Evacetrapib

Phase 1Completed

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cardiovascular Disease

Conditions

Cardiovascular Disease

Trial Timeline

Apr 1, 2013 → Oct 1, 2013

NCT ID

NCT01825889

About Evacetrapib

Evacetrapib is a phase 1 stage product being developed by Eli Lilly for Cardiovascular Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01825889. Target conditions include Cardiovascular Disease.

What happened to similar drugs?

9 of 20 similar drugs in Cardiovascular Disease were approved

Approved (9) Terminated (2) Active (9)

🔄polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3

🔄Dulaglutide + PlaceboEli LillyPhase 3

🔄raloxifene + placeboEli LillyPhase 3

🔄Orforglipron + PlaceboEli LillyPhase 3

✅Rosuvamibe + MonorovaYuhanApproved

✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved

✅Rosuvamibe + MonorovaYuhanApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02497391	Phase 1	Completed	Jul 1, 2015	Nov 1, 2015	Healthy
NCT02226653	Phase 1	Completed	Sep 1, 2014	Apr 1, 2015	Healthy Volunteers
NCT02168803	Phase 1	Completed	May 1, 2014	Dec 1, 2015	Dyslipidemia
NCT01903434	Phase 1	Completed	Jul 1, 2013	Nov 1, 2013	Healthy Volunteers
NCT01825889	Phase 1	Completed	Apr 1, 2013	Oct 1, 2013	Cardiovascular Disease
NCT01836185	Phase 1	Completed	Apr 1, 2013	Oct 1, 2013	Hepatic Insufficiency
NCT01810432	Phase 1	Completed	Mar 1, 2013	Jun 1, 2013	Healthy Volunteers

Competing Products

20 competing products in Cardiovascular Disease

See all competitors

Product	Company	Stage	Hype Score
polypill + Usual cardiovascular medications	Dr. Reddy's Laboratories	Phase 3	37
Dulaglutide + Placebo	Eli Lilly	Phase 3	40
raloxifene + placebo	Eli Lilly	Phase 3	40
Orforglipron + Placebo	Eli Lilly	Phase 3	47
Prasugrel (CS-747) + Clopidogrel	Eli Lilly	Phase 2	35
Rosuvamibe + Monorova	Yuhan	Approved	39
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin	Yuhan	Approved	43
Rosuvamibe + Monorova	Yuhan	Approved	43
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)	Daiichi Sankyo	Approved	43
Lexiscan	Astellas Pharma	Phase 2	35
mirabegron + tamsulosin	Astellas Pharma	Phase 1	29
TRC150094	Torrent Pharmaceuticals	Phase 1/2	32
Lorcaserin hydrochloride + Placebo	Eisai	Approved	43
Lepodisiran Sodium + Placebo	Eli Lilly	Phase 3	44
Retatrutide + Placebo	Eli Lilly	Phase 3	44
Empagliflozin + Placebos	Eli Lilly	Approved	43
Evacetrapib + Placebo	Eli Lilly	Phase 3	32
Placebo + AZD0780	AstraZeneca	Phase 2	35
Risk of low dose aspirin discontinuation	AstraZeneca	Pre-clinical	26
Midazolam + AZD5718	AstraZeneca	Phase 1	29